2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices

Size: px
Start display at page:

Download "2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices"

Transcription

1 2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices UCare requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from UCare before you fill your prescriptions. If you don t get approval, UCare may not cover the drug. UC FVC_ IA ( ) Updated 12/17 U6497 (12/17)

2 Notice of Nondiscrimination UCare complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. UCare does not exclude people or treat them differently because of race, color, national origin, age, disability or sex. We provide aids and services at no charge to people with disabilities to communicate effectively with us, such as TTY line, or written information in other formats, such as large print. If you need these services, contact us at (voice) or toll free at (voice), (TTY), or (TTY). We provide language services at no charge to people whose primary language is not English, such as qualified interpreters or information written in other languages. If you need these services, contact us at the number on the back of your membership card or or toll free at (voice); or toll free at (TTY). If you believe that UCare has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file an oral or written grievance. Oral grievance If you are a current UCare member, please call the number on the back of your membership card. Otherwise please call or toll free at (voice); or toll free at (TTY). You can also use these numbers if you need assistance filing a grievance. Written grievance Mailing Address UCare Attn: Appeals and Grievances PO Box 52 Minneapolis, MN cag@ucare.org Fax: You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue SW Room 509F, HHH Building Washington, D.C , (TDD) Complaint forms are available at

3

4 ACTEMRA ACTEMRA SUBCUTANEOUS PA Covered Uses All FDA-approved indications not otherwise excluded. Plus Polymyalgia Rheumatica (PMR)and patients already started on tocilizumab for a Covered Use. Concurrent Use with a Biologic Disease-Modifying AntirheumaticDrug (DMARD) or Targeted Synthetic DMARD. RA, PMR, GCA - Prescribed by or in consultation with arheumatologist. GCA, PMR 6 mo, RA 3 mos. Cont - RA, GCA - 3 years PMR - 1 year 1

5 PA Other RA, approve The patient has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months (e.g., methotrexate [oral or injectable], leflunomide, hydroxychloroquine, and sulfasalazine)or patient has already has a 3-month trial at least one biologic disease-modifying antirheumatic drug (DMARD) [e.g., Cimzia {certolizumab pegol SC injection}, Enbrel {etanercept SC injection}, Humira {adalimumab SC injection}, Remicade {infliximab IV infusion}, Simponi {golimumab SC injection}, Simponi Aria {golimumab IV infusion}, Kineret {anakinra SC injection}, Orencia {abatacept IV infusion abatacept SC injection}, and Rituxan {rituximab IV infusion}] GCA approve if member has tried one systemic corticosteroid (e.g. Prednisone). PMR approve if the patient has tried one systemic corticosteroid (e.g., prednisone)and The patient has evidence of large vessel vasculitis by angiography or imaging (e.g., magnetic resonance imaging [MRI], computed tomography angiography [CTA], positron emission tomography/computed tomography [PET/CT]). Cont tx RA - pt must have had a response(e.g., less joint pain, morning stiffness, or fatigue, improved function or ADLs, decreased soft tissue swelling in joints or tendon sheaths, improved lab values, reduced dosage of corticosteroids), as determined by the prescriber. Cont tx GCA - patient has had a response (e.g., reduced corticosteroid dose, normalization of acute phase reactants [e.g., erythrocyte sedimentation rate {ESR}, C-reactive protein {CRP}], reduction or resolution of signs or symptoms of GCA), as determined by the prescriber. Cont tx PMR approve if patient has had a response (e.g., reduced corticosteroid dose, normalization of acute phase reactants [e.g., erythrocyte sedimentation rate {ESR}, C-reactive protein {CRP}], reduction or resolution of signs or symptoms of PMR), as determined by the prescriber 2

6 Afinitor AFINITOR PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded. Advanced, unresectable neuroendocrine tumors. Perivascular Epitheloid Cell Tumors (PEComa), Recurrent Angiomyolipoma, Lymphangioleiomyomatosis, relapsed or refractory classical Hodgkin lymphoma, Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL), Advanced Breast Cancer in Patients with HER2-negative Disease Already Started on Afinitor Therapy, Differentiated (i.e. papillary, follicular, and Hürthle cell) Thyroid Carcinoma, Osteosarcoma, Thymomas and Thymic Carcinmoas HER2 status. Advanced HER2-negative breast cancer, hormone receptor (HR) status. Classical Hodgkins Lymphoma patients are 18 years or older Authorization will be for 3 years. 3

7 PA Other Advanced HER2-negative breast cancer, approve if the patient is a postmenopausal woman and has HR+ disease and Afinitor will be used in combination with exemestane or tamoxifen and the patient has tried letrozole, tamoxifen or anastrozole. Renal cell carcinoma (RCC), approve if patient meets one of the following: 1) patient has advanced RCC with predominant clear cell histology AND the patient has tried Inlyta, Votrient, Sutent, or Nexavar OR 2) patient has relapsed or medically unresectable RCC with non-clear cell histology.tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA), approve if the patient requires therapeutic intervention but cannot be curatively resected. NET-approve. Osteosarcoma, approve if the patient has tried standard chemotherapy for osteosarcoma AND the patient has relapsed/refractory or has metastatic disease. Thymomas and Thymic Carcinomas, approve if the patient has tried chemotherapy. Renal angiomyolipoma with TSC-approve. WM/LPL - approve if 1. patient has progressive or relapsed disease OR 2. patient has not responded to primary therapy (e.g., Velcade+/- Rituxan, Velcade with dexamethasone +/-Rituxan, Kyprolis with Rituxan and dexamethasone, cyclophosp/doxorubicin/vincristine/pred/rituxan, Imbruvica, Rituxan, Rituxan with cyclophosphamide and dexamethasone, Thalomid+/- Rituxan OR pt has progressive or relapsed disease. 4

8 Alecensa ALECENSA PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Other Authorization for 3 years Metastatic NSCLC - is anaplastic lymphoma kinase (ALK)-positive AND has either progressed on or is intolerant to Xalkori, or is being used as first-line therapy. 5

9 Alunbrig ALUNBRIG PA Covered Uses All FDA-approved indication not otherwise excluded. ALK status, treatment history and results Other Authorization will be for 3 years. Metastatic NSCLC, patient new to therapy must be ALK-positive AND experienced progression or intolerance while on Xalkori, Zykadia or Alecensa 6

10 AMPYRA AMPYRA PA Covered Uses All FDA-approved indications not otherwise excluded. Other Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS. Authorization will be for 3 years Used to improve mobility in a patient with MS. 7

11 ANABOLIC STEROIDS oxandrolone PA Covered Uses All FDA-approved indications not otherwise excluded. Girls w/ Turner's Syndrome or Ullrich-Turner Syndrome (oxandrolone only), management of protein catabolism w/ burns or burn injury (oxandrolone only), AIDS wasting and cachexia. Authorization will be for 12 months, unless otherwise specified. Other 8

12 Androxy ANDROXY PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Authorization will be for 12 months Other 9

13 ARANESP ARANESP (IN POLYSORBATE) INJECTION SOLUTION ARANESP (IN POLYSORBATE) INJECTION SYRINGE 100 MCG/0.5 ML, 150 MCG/0.3 ML, 200 MCG/0.4 ML, 25 MCG/0.42 ML, 300 MCG/0.6 ML, 40 MCG/0.4 ML, 500 MCG/ML, 60 MCG/0.3 ML PA Covered Uses All FDA-approved indications not otherwise excluded worded as anemia associated with chronic renal failure (CRF), including patients on dialysis and not on dialysis, and worded as anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia. Anemia due to myelodysplastic syndrome (MDS) CKD and MDS - Authorization will be for 6 months, Other - Authorization will be for 4 months 10

14 PA Other Confirmation of adequate iron stores at intiation of therapy (eg, prescribing information recommends supplemental iron therapy when serum ferritin is less than 100 mcg/l or when serum transferrin saturation is less than 20%). Anemia w/crf on and not on dialysis. A hemoglobin (Hb) of less than 10.0 g/dl for patients 18 years and older and less than or equal to 11 g/dl for children required for start,hb has to be less than or equal 11.5 g/dl for patients 18 years of age and older or less than or equal to 12 g/dl in children if currently receiving epoetin alfa (EA) or Aranesp. Anemia due to myelosuppressive chemotx,hb is 10.0 g/dl or less to start.hb less than or equal to 12.0 g/dl if currently on epoetin alfa EA. MDS, approve tx if Hb is 10 g/dl or less or serum erythropoietin level is 500 mu/ml or less to start. 11

15 ARCALYST ARCALYST PA Covered Uses All FDA-approved indications not otherwise excluded. Plus patient already started on rilonacept for Muckle Wells Syndrome (MWS) or Familial Cold Autoinflammatory Syndrome (FCAS). Rilonacept should not be given in combination with biologic therapy (e.g.tumor necrosis factor (TNF) blocking agents (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), anakinra, or canakinumab). Other Initial tx CAPS-Greater than or equal to 12 years of age. Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, or dermatologist. Initial approval of 3 months. Subsequent authorization for 3 years if patient had a response. CAPS renewal - approve if they have had a response and are continuing therapy to maintain response/remission. 12

16 AUBAGIO AUBAGIO PA Covered Uses All FDA-approved indications not otherwise excluded. Plus patients already started on Aubagio for a Covered Use. Concurrent use of Aubagio with other disease-modifying agents used for multiple sclerosis (MS) [eg, Avonex, Rebif, Betaseron, Extavia, Copaxone, Tysabri, Tecfidera, or Gilenya]. MS, patient must have a relapsing form of MS (RRMS, SPMS with relapses, or PRMS). MS, previous MS therapies tried. Other Prescribed by or in consultation with a neurologist or MS specialist. Authorization will be for 3 years. For use in a relapsing form of MS. 13

17 Austedo AUSTEDO PA Covered Uses All FDA-approved indications not otherwise excluded Diagnosis and previous medications tried Other Prescribed by or in consultation with a neurologist or psychiatrist Authorization will be for 1 year Chorea associated with Huntington's Disease - approve if, according to the prescribing physician, the patient has previously tried brand or generic tetrabenazine tablets. 14

18 AVONEX AVONEX (WITH ALBUMIN) AVONEX INTRAMUSCULAR PEN INJECTOR KIT AVONEX INTRAMUSCULAR SYRINGE KIT PA Covered Uses All FDA-approved indications not otherwise excluded. Concurrent use of other disease-modifying agent used for multiple sclerosis (ie, interferon beta-1a, interferon beta-1b, glatiramer, natalizumab, fingolimod, teriflunomide, dimethyl fumarate DR) Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS. Prescribed by or after consultation with a neurologist or an MS specialist. Authorization will be for 3 years. Other 15

19 BETASERON BETASERON SUBCUTANEOUS KIT EXTAVIA PA Covered Uses All FDA-approved indications not otherwise excluded. Concurrent use with other disease-modifying agent used for multiple scelorosis (ie, interferon beta-1a, glatiramer, natalizumab, fingolimod, teriflunomide, dimethyl fumerate ER) Multiple Sclerosis (MS) diagnosis worded or described as patients with a diagnosis of MS or have experienced an attack and who are at risk of MS. Prescribed by or after consultation with a neurologist or an MS specialist. Authorization will be for 3 years. Other 16

20 BOSULIF BOSULIF ORAL TABLET 100 MG, 500 MG PA Covered Uses All FDA-approved indications not otherwise excluded. Plus patients already started on Bosulif for a covered indication. Diagnosis for which Bosulif is being used. For chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) status of the leukemia must be reported. For CML, prior therapies tried must be reported to confirm resistance or intolerance. Other Authorization will be for 3 years. For CML, patient must have Ph-positive CML and have tried one other tyrosine kinase inhibitor indicated for use in Philadelphia chromosome positive CML (e.g., Gleevec [imatinib tablets] Sprycel [dasatinib tablets], or Tasigna [nilotinib capsules]). 17

21 CABOMETYX CABOMETYX PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Plus patients with Non-Small Cell Lung Cancer with RET Gene Rearrangements. Plus patients already taking Cabometyx for a Covered Use. Diagnosis, medication history, histology, RET gene rearrangement status Authorization will be for 3 years Other Advance Renal Cell Carcinoma-Patients must meet both 1 AND 2. 1) Patient has RCC with predominant clear-cell histology 2) Patient has tried one tyrosine kinase inhibitor therapy (e.g., Sutent [sunitinib malate capsules], Votrient [pazopanib tablets], Inlyta [axitinib tablets], Nexavar [sorafenib tosylate tablets]) OR patient has RCC with non-clear cell histology 18

22 Caprelsa CAPRELSA ORAL TABLET 100 MG, 300 MG PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded. Plus Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma and NSCLC with RET Gene Rearrangements. Other Authorization will be for 3 years. MTC - approve. DTC - approve if refractory to radioactive iodine therapy. 19

23 Chenodal CHENODAL PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded Other Authorization will be for 1 year For the treatment of gallstones, approve if the patient has tried or is currently using an ursodiol product. 20

24 COMBINATION BETA-2 AGONIST/CORTICOSTEROID INHALER DULERA INHALATION HFA AEROSOL INHALER MCG/ACTUATION, MCG/ACTUATION PA Covered Uses All medically-accepted indications not otherwise excluded. Diagnosis of asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, or postinfectious cough (i.e., cough persisting after an acute respiratory infection has resolved). Authorization will be for 3 years Other 21

25 COMETRIQ COMETRIQ PA Covered Uses All medically-accepted indications not otherwise excluded worded as NSCLC with RET gene Rearrangements. Authorization will be for 3 years Other 22

26 COPAXONE glatiramer GLATOPA PA Covered Uses All FDA-approved indications not otherwise excluded. Given in combination with another disease-modifying agent used for MS(such as, Rebif, Betaseron, Tysabri, Gilenya, Aubagio, and Tecfidera) Diagnosis of Multiple Sclerosis(MS) or patient has experienced an attack and is at risk for MS. Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis. Authorization will be for 3 years Other 23

27 Corlanor CORLANOR PA Covered Uses All FDA-approved indications not otherwise excluded Previous use of a Beta-blocker, LVEF, sinus rhythm, and resting HR Other Prior Authorization will be approved for 12 months. HF in pts not currently receiving Corlanor - must all of the following: have LVEF of less than or equal 35 percent, have sinus rhythm and a resting HR of greater than or equal to 70 BPM, AND tried or is currently receiving a Beta-blocker for HF (e.g., metoprolol succinate sustained-release, carvedilol, bisoprolol, carvedilol ER) unless the patient has a contraindication to the use of beta blocker therapy (e.g., bronchospastic disease such as COPD and asthma, severe hypotension or bradycardia). HF in pts currently receiving Corlanor - had a LVEF of less than or equal to 35 percent prior to initiation of Corlanor therapy AND has tried or is currently receiving a Betablocker for HF unless the patient has a contraindication to the use of beta blocker therapy. 24

28 COSENTYX COSENTYX COSENTYX (2 SYRINGES) COSENTYX PEN COSENTYX PEN (2 PENS) PA Covered Uses All FDA-approved indications not otherwise excluded. Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) Diagnosis, previous medication use 18 years of age and older AS prescribed by or in consultation with a rheumatologist. PP prescribed by or in consultation with a dermatologist. PsA prescribed by or in consultation with a rheumatologist or a dermatologist. Intial AS, PP, PsA 3 mo Con AS, PP, PsA 3 years 25

29 PA Other Initial PP - approve if patient meets ONE of the following conditions: Patient has tried at least at least one traditional systemic agent for psoriasis (e.g., methotrexate [MTX], cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light [PUVA]) for at least 3 months, unless intolerant OR patient has already has a 3-month trial or previous intolerance to at least one biologic (e.g., Enbrel [etanercept for SC injection], Humira [adalimumab for SC injection], an infliximab product [e.g., Remicade, Inflectra], Stelara [ustekinumab for SC injection], or Taltz [ixekizumab for SC injection]) OR b)patient has a contraindication to methotrexate (MTX), as determined by the prescribing physician. Cont tx PP - patient has responded, as determined by the prescriber Cont tx AS - approve if patient has had a response (e.g., decreased pain or stiffness, improved function or activities of daily living), as determined by the prescriber. Cont tx PsA - approve if the patient has responded (e.g., less joint pain, morning stiffness, or fatigue improved function or activities of daily living decreased soft tissue swelling in joints or tendon sheaths improvements in acute phase reactants [for example, C-reactive protein]), as determined by the prescriber. 26

30 Cotellic COTELLIC PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Plus patients using Cotellic for a covered use. Melanoma initial - must have BRAF V600 mutation. Other Authorization for 3 years Melanoma, Unresectble or Metastatic: Approve in patients who meet the following criteria: The patient has a BRAF V600 mutation AND Cotellic is being prescribed in combination with Zelboraf (vemurafenib tablets Zelboraf.) 27

31 Daliresp DALIRESP PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded Chronic Obstructive Pulmonary Disease (COPD), medications tried. Other Authorization will be for 1 year COPD, approve in patients who meet all of the following conditions: Patients has severe COPD or very severe COPD, AND Patient has chronic bronchitis, AND Patient has a history of exacerbations, AND Patient has tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, formoterol], long-acting anticholinergic (eg, tiotropium), inhaled corticosteroid (eg, fluticasone). 28

32 DUPIXENT DUPIXENT PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Other Diagnosis, prescriber specialty, other medications tried and length of trials 18 years of age and older (initial and continuation) Prescribed by or in consultation with a an allergist, immunologist or dermatologist (initial and continuation) Initial-16 weeks, Continuation-1 year Initial Therapy- Patient meets all both of the following criteria: Patient has used at least one medium-, medium-high, high-, and/or super-high-potency prescription topical corticosteroid for at least 28 consecutive days OR patient has atopic dermatitis affecting ONLY the face, eyes/eyelids, skin folds, and/or genitalia and has tried tacrolimus ointment for at least 28 consecutive days AND Inadequate efficacy was demonstrated with these previously tried topical prescription therapies, according to the prescribing physician. Continuation- Approve if the patient has responded to Dupixent therapy as determined by the prescribing physician (e.g., marked improvements erythema, induration/papulation/edema, excoriations, and lichenification, reduced pruritus, decreased requirement for other topical or systemic therapies, reduced body surface area (BSA) affected with atopic dermatitis, or other responses observed). 29

33 DYSPORT DYSPORT PA Covered Uses All FDA-approved indications not otherwise excluded. Plus Spasticity and anal fissures. Use in the management of cosmetic uses. Authorization for 12 months Other 30

34 ENBREL ENBREL ENBREL MINI ENBREL SURECLICK PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Plus Behcet's Disease, Graft-Versus-Host Disease, Pyoderma Gangrenosum, Scleritis (sterile corneal ulceration), Spondylarthritis, Still's Disease, and Uveitis. Concurrent Use with a Biologic DMARD or Targeted Synthetic DMARD RA, AS, JIA/JRA, SpA, SD - prescribed by or in consultation with a rheumatologist. PP, PG - prescribed by or in consultation with a dermatologist. PsA - prescribed by or in consultation with a rheumatologist or a dermatologist. Behcet's prescribed by or in consultation with a rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist. GVHD prescribed by or in consultation with an oncologist, hematologist, or a physician in a transplant center. Scleritis, Uveit - ophthalm. Intial RA, AS, JIA, PP, PsA 3 mo Behcet's, GVHD, PG, SpA, Uv 1 year Cont RA, AS, JIA, PP, PsA 3 yrs 31

35 PA Other Initial RA - approve if The patient has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months OR patient has tried a 3-month trial at least one biologic disease-modifying antirheumatic drug (DMARD). JIA/JRA - approve if patients meets the following: Patient has tried one other agent for this condition or a biologic disease-modifying antirheumatic drug OR Patient will be starting on Enbrel concurrently with methotrexate (MTX), sulfasalazine, or leflunomide OR Patient has an absolute contraindication to methotrexate (MTX), sulfasalazine, or leflunomide OR Patient has aggressive disease, as determined by the prescribing physician. PP initial - approve if The patient has tried at least at least one traditional systemic agent for psoriasis (e.g., methotrexate [MTX], cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light [PUVA]) for at least 3 months, unless intolerant OR the patient has already has a 3-month trial or previous intolerance to at least one biologic. Behcet's tried at least one conventional therapy. GVHD approve if Patient has tried one conventional treatment or is currently receiving one of these medications. PG approve if patient has tried one systemic corticosteroid OR one other immunosuppressant for at least 2 mo or was intolerant. Scleritis - pt has tried 1 other therapy (NSAID, IV corticosteroid, or immunosuppressant). SpA - The patient has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet AND has tried at least ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) OR The patient has axial spondyloarthritis. Still's Disease - Patient has tried one corticosteroid AND Patient has tried one conventional synthetic disease-modifying antirheumatic drug (DMARD) such as methotrexate (MTX) given for at least 2 months or was intolerant. Uveitis - The patient has tried one of the following therapies: periocular, intraocular, or systemic corticosteroids [for example, triamcinolone, betamethasone, methylprednisolone, prednisone] immunosuppressives (e.g., methotrexate [MTX], mycophenolate mofetil, cyclosporine, azathioprine, cyclophosphamide) Humira or Remicade for this condition. Cont tx approve if the patient has had a response as determined by the prescriber. 32

36 Entresto ENTRESTO ORAL TABLET MG, MG, MG PA Covered Uses All FDA-approved indications not otherwise excluded. Combination therapy with an ACE inhibitor/ace inhibitor containing product, an ARB containing product, or Tekturna (aliskiren tablets) or a Tekturna-Containing Product in patients with diabetes Must have LVEF less than or equal to 40 percent prior to initiation with Entresto Other Prescribed by, or in consultation with, a cardiologist Prior Authorization will be approved for 12 months. Chronic HF - Must meet both of the following: Have tried ONE ACE inhibitor for HF (e.g., captopril, enalapril, lisinopril, quinapril, fosinopril) or ARB(e.g. valsartan, candesartan) or have a contraindication to use an ACE inhibitor or ARB (e.g., history of angioedema, hypotension, impaired renal function, hyperkalemia) AND Have tried or is currently receiving one beta blocker for heart failure treatment (e.g., metoprolol succinate sustained release, carvedilol, bisoprolol, Coreg CR) and/or Corlanor or have a contraindication to use of beta blocker therapy (e.g., bronchospastic disease such as COPD and asthma, severe hypotension). 33

37 Epclusa EPCLUSA PA Covered Uses Other All FDA-approved indications not otherwise excluded. Plus patients started on Epclusa for a Covered Use. will be applied consistent with current AASLD/IDSA guidance and, if not available, FDA labeling. Genotype, prescriber specialty, other medications tried or used in combination with requested medication 18 years of age or older Must be prescribed by (or had a documented consult with) a gastroenterologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. will be applied consistent with current AASLD/IDSA guidance or FDA label. Initial Treatment for All Genotypes - Must have tried and failed Mavyret or have contraindication to Mavyret. Treatment Experienced for All Genotypes - Must have tried and failed Vosevi and Mavyret or have an contraindication for Vosevi and Mavyret. will be applied consistent with current AASLD/IDSA guidance and, if not available, FDA labeling. 34

38 EPOGEN AND PROCRIT EPOGEN INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML PROCRIT PA Covered Uses All FDA-approved indications not otherwise excluded worded as anemia associated with chronic renal failure (CRF), including patients on dialysis and not on dialysis, and worded as anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia. Anemia due to myelodysplastic syndrome (MDS). Plus anemia in patients with HIV(with or without zidovudine). Patients using for perisurgical adjuvant therapy. CKD and MDS - Authorization will be for 6 months, Perisurgical - 1 month, Other - 4 months 35

39 PA Other Confirmation of adequate iron stores at initiation of therapy (eg, prescribing information recommends supplemental iron therapy when serum ferritin is less than 100 mcg/l or when serum transferrin saturation is less than 20%). CRF anemia in patients on and not on dialysis. Hemoglobin (Hb) of less than 10.0 g/dl for adults or less than or equal to 11 g/dl for children to start. Hb less than or equal to 11.5 g/dl for adults or 12 g/dl or less for children if currently on epoetin alfa or Aranesp. Anemia w/myelosuppressive chemotx. pt must be currently receiving myelosuppressive chemo and Hb 10.0 g/dl or less to start. Hb less than or equal to 12.0 g/dl if currently on epoetin alfa or Aranesp. MDS, approve if Hb is 10 g/dl or less or serum erythropoietin level is 500 mu/ml or less to start. Currently receiving Aranesp or EA, approve if Hb is 12.0 g/dl or less. Anemia in HIV (with or without zidovudine), Hb is 10.0 g/dl or less or endogenous erythropoetin levels are 500 munits/ml or less at tx start. Currently on EA approve if Hb is 12.0 g/dl or less. Perisurgical adjuvant therapy, patient is undergoing hip or knee surgery, has Hgb between 10 and 13 g/dl, is not a candidate for autologous blood transfusion. 36

40 Erivedge ERIVEDGE PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded BCC (La or Met) - must not have had disease progression while on Odomzo. Other Authorization will be for 12 months Locally advanced basal cell carcinoma (LABCC), approve if 1. the patient's BCC has recurred following surgery or radiation, OR 2. the patient is not a candidate for surgery and radiation therapy. 37

41 ESBRIET ESBRIET PA Covered Uses All FDA-approved indications not otherwise excluded. Used with Ofev(nintedanib) Other The patient is aged greater than or equal to 40 years old. The agent has been prescribed by, or in consultation with, a pulmonologist. Authorization will be for 3 years Idiopathic Pulmonary Fibrosis - At baseline (before therapy initiation), patients have an FVC greater than or equal to 50% of the predicted value AND The diagnosis of IPF is confirmed by one of the following (i or ii) i. Findings on high-resolution computed tomography (HRCT) indicates usual interstitial pneumonia (UIP), OR ii.a surgical lung biopsy demonstrates usual interstitial pneumonia (UIP). 38

42 FARYDAK FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG PA Covered Uses All FDA-approved indications not otherwise excluded. Other Authorization for 12 months MM - must be used in combination with Velcade and dexamethasone AND previously tried Velcade and one immunomodulatory drug (i.e., Thalomid, Revlimid, or Pomalyst). 39

43 Firazyr FIRAZYR PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded Prescribed by, or in consultation with, an allergist/immunologist or a physican that specializes in the treatment of HAE or related disorders. Authorization will be for 1 year Other 40

44 FORTEO FORTEO PA Covered Uses All FDA-approved indications not otherwise excluded. Concomitant use with other medications for osteoporosis (e.g., Prolia [denosumab for SC injection], bisphosphonates [alendronate, risedronate, ibandronate, zoledronic acid injection {Reclast}], calcitonin nasal spray, Tymlos [abaloparatide injection for SC use]), except calcium and Vitamin D. Previous Use of Forteo and/or Tymlos For a Combined Total No Greater than 2 Years During a Patient's Lifetime. Other Authorization will be for up to 2 years in a patient's lifetime. Treatment of PMO, osteoporosis in men, and glucocorticoidinduced osteoporosis, approve if pt has tried one oral bisphosphonate for at least 12 months with an inadequate response OR the patient has experienced intolerability to an oral bisphosphonate OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR pt has severe renal impairment (creatinine clearance less than 35 ml/min) or CKD or pt has had multiple osteoporotic fractures. 41

45 GILENYA GILENYA PA Covered Uses All FDA-approved indications not otherwise excluded. Must not be given in combination with Avonex, Betaseron, Extavia, Copaxone, Rebif or Tysabri. Other Authorization will be for 12 months. Must have tried one of the following injectable medications: Avonex (interferon beta-1a IM), Rebif (interferon beta-1a SC), Betaseron or Extavia (interferon beta 1b) or Copaxone (glatiramer acetate), or that the patient is unable to administer injections such as these due to dexterity issues or visual impairment, or has tried Tysabri. 42

46 GILOTRIF GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG PA Covered Uses All FDA-approved indications not otherwise excluded. Diagnosis of metastatic Non-Small Cell Lung Cancer (NSCLC) Other Authorization will be for 12 months Patient must have epidermal growth factor receptor (EGFR) exon 19 deletion as detected by a Food and Drug Administration (FDA)- approved test OR the patient does not have exon 21 (L858R) substitution as detected by an FDA-approved test. 43

47 Gleevec imatinib oral tablet 100 mg, 400 mg PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA approved indications not otherwise excluded. Plus chordoma, advanced or unresectable fibromatosis (desmoid tumors), ckit positive advanced/recurrent or metastatic melamona, and pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor, Graft Versus Host Disease (Chronic) and patients continuing treatment for an approved use. Diagnosis. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. Other Authorization will be for 3 years. GVHD approve for 1 year. For ALL/CML, new patient must have Ph-positive for approval of imatinib.mds/mpd condition is associated with platelet derived growth factor receptor gene rearrangements. GVHD approve if patient has tried one conventional systemic treatment for graft versus host disease (e.g., corticosteroids [methylprednisolone, prednisone], cyclosporine, tacrolimus, mycophenolate mofetil, Imbruvica [ibrutinib capsules]). 44

48 GLUCAGON-LIKE PEPTIDE -1 AGONISTS BYDUREON SUBCUTANEOUS PEN INJECTOR BYDUREON SUBCUTANEOUS SUSPENSION,EXTENDED REL RECON BYETTA SUBCUTANEOUS PEN INJECTOR 10 MCG/DOSE(250 MCG/ML) 2.4 ML, 5 MCG/DOSE (250 MCG/ML) 1.2 ML TRULICITY PA Covered Uses All FDA-approved indications not otherwise excluded. Authorization will be for 3 years Other 45

49 GROWTH HORMONE GENOTROPIN GENOTROPIN MINIQUICK HUMATROPE NORDITROPIN FLEXPRO NUTROPIN AQ NUTROPIN AQ NUSPIN OMNITROPE SAIZEN CLICK.EASY SAIZEN SUBCUTANEOUS RECON SOLN 5 MG SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG ZORBTIVE PA Covered Uses All FDA-approved indications not otherwise excluded. Growth hormone (GH) deficiency (DF). Non-GH deficient short stature (idiopathic short stature, ISS). Turner's syndrome (TS). SHOX (short stature homeobox-containing gene) deficiency. Chronic kidney disease (CKD) Prader-Willi syndrome (PW). Noonan syndrome (NS). Short bowel syndrome (SBS) Use in the management of acute critical illness due to complications of surgery, trauma, or with acute respiratory failure, as antiaging therapy, to improve functional status in elderly, somatopause, enhancement of athletic ability, bone marrow transplant (BMT) without total body irradiation, bony dysplasias, burn injury, cardiac transplantation, central precocius puberty, chronic fatigue syndrome, congenital adrenal hyperplasia, constitutional delay of growth and puberty, corticosteroid-induced short stature including a variety of chronic glucocorticoid-dependent conditions, such as asthma, juvenile rheumatoid arthritis, after renal, heart, liver, or BMT, Crohn's disease, cystic fibrosis, dilated cardiomyopathy/heart failure, end-stage renal disease in adults undergoing hemodialysis, Down's syndrome, familial dysautonomia, fibromyalgia, HIV-infected patients with alterations in body fat distribution, infertility, kidney transplant patients (children) with a functional renal allograft, liver transplantation, multiple system atrophy, myelomeningocele, obesity, osteogenesis imperfecta, osteoporosis (postmenopausal, idiopathic in men, glucocorticoid-induced), thalassemia, and X-linked hypophosphatemic rickets (familial hypophosphatemia, hypophosphatemic rickets). 46

50 PA Child/adol GH DF initial tx, eval by an endocrin, documented GH stim test w/gh response less than 10 ng/ml AND base Ht less than the 10th pct for gender/age + pretx Ht growth rate (GR) child less than 3 yrs of less than 7 cm/yr and child greater than or equal to 3 yrs of less than 4 cm/yr OR child/adol less than 18 yrs of age GR less than the 10th pct for age/gender based on min 6 mo data.child w/brain radiation does not have to meet bas Ht crit.congenital hypopituit does not have to meet Ht or GR crit.child w/hypophysectomy,approve.child/adol GH DF cont tx, GR increased by 4 cm/yr or more in most recent yr (MRY) + epiphyses open (between 12 and 18 yrs),both crit exclude adol w/hypopituit.review GR annually.adoles/yng adult w/completed linear growth (GR less than 2 cm/yr), review for adult GH DF.Greater than 18 yrs,gr increased by 4 cm/yr or more in MRY AND epiphyses open, auth not allowed if midparental ht attained.iss child w/open epiphyses,6 mo trial if base Ht less than 5th pct + pretx GR child greater than or equal to 7 yrs of less than 4 cm/yr and child 3 or more yrs of less than 4 cm/yr OR child any age GR less than the 10th pct for age/gender based on min 6 mo of data and has condition which GH effective + endocrinol certifies via bone-age x-ray, + the pt doesnt have constitutional delay of growth and puberty (CDGP).Auth after initial tx based on adequate clinical response (annualized GR doubles).cont tx, at least 7 yrs and received somatropin on 6 mo trial, if GR has doubled in comparison to previous yr. At least 7 and less than 12 yrs, GR increased by 4 cm/yr or more in MRY. At least 12 and less than or equal to 18 yrs), GR increased by 4 cm/yr or more in MRY AND epiphyses open).greater than 18 yrs, GR increased by 4 cm/yr or more in MRY,+ epiphyses open auth not allowed if midparental ht attained.adult GH DF or PW/trans adoles, eval by endocrinol (start and annually).ns/shox/child PW, eval by an endocrinol, CKD, eval by an endocrin or nephrologist. Child/adolesc w/gh DF (initial tx), adolescent is less than or equal to 18 years of age.ts, children. SHOX/CRI/NS, children/adolescents.hiv infection w/wasting or cachexia, less than or equal to 18 years of age.sbs/hiv cachexia/wasting, adults. For adults, the endocrinologist must certify that the somatropin is not being prescribed for anti-aging therapy or to enhance athletic ability. 47

51 PA GH DF 12 mos.sbs 4-8wks/yr.Non-GH DF ISS 6 mos.hiv wast/cach 24 wks. Other 48

52 HUMIRA HUMIRA PEDIATRIC CROHN'S START HUMIRA PEN HUMIRA PEN CROHN'S-UC-HS START HUMIRA PEN PSORIASIS-UVEITIS HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML PA Covered Uses All ly accepted indications not otherwise excluded including Behcet's Disease, Pyoderma Grangrenosum, Sarcoidosis, Scleritis (Sterile Conreal Ulceration), Spondyloarthritis plus patients already started on adalimumab for a Covered Use. Concurrent use with biologic DMARD or targeted synthetic DMARD (does not include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide). Moderate or severe heart failure (NYHA Class III or IV). History of treated lymphoproliferative disease. Multiple sclerosis or other demyelinating disorder. None Crohn's Disease 6 years old or older. RA/JIA/JRA/AS/SpA, prescribed by or in consultation with rheumatologist. Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. PP or PG - prescribed by or in consultation with a dermatologist. UC/ CD, prescribed by or in consultation with a gastroenterologist. Uveitis/Scleritis prescribed by or in consultation with a ophthalmologist. Sarcoidosis prescribed by or in consultation with a pulmonologist, ophthalmologist, or dermatologist Initial RA/AS/CD/JIA/JRA/HS/PP/PsA/UC 3 months Cont RA/AS/CD/JIA/JRA/HS/PP/PsA/UC 3 yr others 1yr 49

53 PA Other For RA, the patient must have had a trial with a conventional DMARD regimen (eg, methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide) for 3 months unless the patient experienced intolerance, or the patient has tried and failed at least one biologic DMARD for 3 months unless the patient experienced intolerance (ie, patients not required to "step back" after trying a biologic). For JIA/JRA, tried another agent (eg, MTX, sulfasalazine, leflunomide, NSAID, or biologic DMARD (eg, etanercept, abatacept, infliximab, anakinra, tocilizumab) or will be starting on adalimumab concurrently with MTX, sulfasalazine, or leflunomide. Approve without trying another agent if the patient has absolute contraindication to MTX, sulfasalazine, or leflunomide or if the patient has aggressive disease. For plaque psoriasis (PP), the patient has tried a systemic therapy (eg, MTX, CSA, acitretin, etanercept, infliximab, or ustekinumab) for 3 months or PUVA for 3 months, or the patient experienced an intolerance to a trial of at least one systemic therapy (oral or biologic therapy), or the patient has a contraindication to one oral agent for psoriasis. For CD, the patient has tried corticosteroid (CS) or if CS contraindicated or if currently on CS or if the patient has tried one other agent for CD (eg, azathioprine, 6-MP, MTX, certolizumab, adalimumab, ustekinumab, vedolizumab) or the patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas or the patient has had ileocolonic resection. For UC, the patient has tried a systemic therapy (eg, 6-mercaptopurine, azathioprine, CSA, tacrolimus, infliximab, or a corticosteroid for 2 months or was intolerant to one of these agents, or the patient has pouchitis and has tried therapy with an antibiotic, probiotic, corticosteroid enema, or mesalamine (Rowasa) enema. HS approve if the patient has tried ONE other therapy (e.g., intralesional or oral corticosteroids [such as triamcinolone, prednisone], systemic antibiotics [for example, clindamycin, dicloxacillin, erythromycin], isotretinoin). UV approve if patient has tried ONE of the following therapies: periocular, intraocular, or systemic corticosteroids, immunosuppressives (e.g., methotrexate [MTX], mycophenolate mofetil, cyclosporine, azathioprine, cyclophosphamide) Enbrel (etanercept SC injection), or Remicade. PG approved if patient has tried one systemic corticosteroid () OR Patient has tried one other immunosuppressant for at least 2 months or was intolerant to one of these agents. Sarcoidosis - approve if pt has tried at least 1 corticosteroid for this condition AND has tried at least one immunosuppressive agent. Scleritis approve if pt has tried 1 therapy (NSAID, IV corticosteroid, or immunosuppressive agent). SpA approve if pt has arthritis primarily in the knees, ankles, 50

54 PA elbows, wrists, hands, and/or feet AND has tried at least ONE conventional drug DMARD. Cont - pt has had a response, as determined by prescriber 51

55 Hyqvia HYQVIA PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Authorization will be for 1 year. Other 52

56 Ibandronate ibandronate intravenous PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded Authorization will be for 12 months. 53

57 PA Other Treatment of postmenopausal osteoporosis, must meet ONE of the following 1. T-score (current or at any time in the past) at or below -2.5 at the lumbar spine, femoral neck, or total hip, 2. has had osteoporotic fracture, 3. had a T-score (current or at any time in the past) at or below -2.0 at the lumbar spine, femoral neck, or total hip and the physician believes the patient is at high risk for fracture AND has had an inadequate response to oral bisphosphonate therapy after a trial duration of 12 months as determined by the prescribing physician (e.g., ongoing and significant loss of bone mineral density (BMD), lack of BMD increase), had an osteoporotic fracture while receiving oral bisphosphonate therapy, or experienced intolerability to an oral bisphosphonate (e.g., severe GI-related adverse effects) OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a preexisting GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid). 54

58 IBRANCE IBRANCE PA Covered Uses All FDA approved indications not otherwise excluded. Other Authorization for 12 months Breast cancer - approve in postmenopausal women with advanced (metastatic) ER positive disease, and HER2-negative breast cancer when used in combination with letrozole. 55

59 Imbruvica IMBRUVICA PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded. Diagnosis Other Authorization will be for 3 years, GVHD authorization will be for 1 year. Marginal Zone Lymphoma pt has tried Rituxan (rituximab for IV infusion) or according to the prescribing physician, Rituxan is contraindicated for use in this patient. GVHD the patient has tried one conventional systemic treatment for graft versus host disease (e.g., corticosteroids [methylprednisolone, prednisone], cyclosporine, tacrolimus, mycophenolate mofetil, imatinib). 56

60 IMMUNE GLOBULIN CARIMUNE NF NANOFILTERED INTRAVENOUS RECON SOLN 12 GRAM, 6 GRAM GAMMAGARD LIQUID PRIVIGEN PA Covered Uses All FDA-approved indications not otherwise excluded. For Vivaglobin, Hizentra prescribed with one of the following physician specialists: an allergist/immunologist, immunologist, otolaryngologist (ear nose and throat [ENT] physician), pulmonologist, or an infectious disease specialist Authorization will be for 12 months. 57

61 PA Other For Gammunex-C, Gammaked, Gammagard liquid given SC and Vivaglobin, Hizentra, needs to be used for the treatment of a primary humoral or combined immune deficiency, which includes common variable immunodeficiency (CVID), X-linked agammaglobulinemia, severe combined immunodeficiencies (SCID), Wiskott-Aldrich syndrome, hyper-igm syndromes (X-linked or autosomal recessive), other combined immunodeficiencies with significant hypogammaglobulinemia or antibody production defect, and unspecified hypogammaglobulinemia. For Gammunex-C, Gammked, Gammagard, other IVIG given IV, need documented diagnosis, prescriber specialty. For Vivaglobin, Hizentra, diagnoses Common variable immunodeficiency (CVID) and Unspecified hypogammaglobulinemia patient has documented history of significant recurrent or persistent, severe bacterial infections (such as recurrent pneumonias, frequent episodes of bacterial infections such as sinusitis, otitis, bronchitis, skin structure infections, or infections of the gastrointestinal tract) according to the prescribing physician that are not responding to antibiotics or prophylactic antibiotics or member has interfering hypersensitivities, other disorders increasing susceptibility to infection need to have been sought out and treated if exist, patient has reduced IgG level or reduced IgG1 and IgG3 levels or IgG1 reduction. Other immune deficiencies for Hizentra, Vivaglobin, patient has frequent and severe infections. 58

62 Inlyta INLYTA PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded. Plus, Differentiated (i.e., papillary, follicular, and Hurthle) Thyroid Carcinoma. Other Authorization will be for 3 years. Advanced renal cell carcinoma, approve. Differentiated thyroid cancer, approve if patient is refractory to radioactive iodine therapy. 59

63 Iressa IRESSA PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA approved indications not otherwise excluded. Other Authorization will be for 3 years. Metastatic NSCLC - The patient has epidermal growth factor receptor (EGFR) exon 19 deletions OR has exon 21 (L858R) substitution mutations as detected by an FDA-approved test. 60

64 Jakafi JAKAFI PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded. Other Authorization will be for 3 years. For polycythemia vera patients must have tried hydroxyurea 61

65 Kadcyla KADCYLA PA Covered Uses All FDA-approved indications not otherwise excluded from Part D. All FDA-approved indications not otherwise excluded. Authorization will be for 3 years. Other 62

66 KALYDECO KALYDECO ORAL TABLET PA Covered Uses All FDA-approved indications not otherwise excluded. Other Authorization will be for 12 months. Must have tested positive for G551D mutation in the CFTR gene. 63

67 LEMTRADA LEMTRADA PA Covered Uses Other All FDA approved indications not otherwise excluded. Lemtrada should not be given in combination with other diseasemodifying agents used for MS (e.g., Betaseron, Extavia, Rebif, Copaxone, Avonex, Plegridy, Glatopa, Gilenya, Aubagio, Tecfidera, Tysabri or Zinbryta). The patient has a relapsing form of MS (relapsing forms of MS are RRMS, SPMS with relapses, and PRMS) The patient is 17 years of age or older. Lemtrada is prescribed by or in consultation with a neurologist or a physician that specializes in the treatment of MS. Authorization for 12 months The patient has had an inadequate response according to the prescribing physician to two of the following medications for MS: Avonex, Rebif, Betaseron, Extavia, Copaxone, Plegridy, Gilenya, Aubagio, Tecfidera, or Tysabri. 64

2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices

2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices 2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices UCare requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from UCare

More information

2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices

2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices 2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices UCare requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from UCare

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

2019 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2019 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2019 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) UCare requires your physician to get prior authorization for certain

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

2017 PRIOR AUTHORIZATION CRITERIA

2017 PRIOR AUTHORIZATION CRITERIA 2017 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices UCare requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from UCare

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

2018 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) UCare requires your physician to get prior authorization for certain

More information

2018 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) UCare requires your physician to get prior authorization for certain

More information

Stelara. Stelara (ustekinumab) Description

Stelara. Stelara (ustekinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara

More information

2019 PRIOR AUTHORIZATION CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

2019 PRIOR AUTHORIZATION CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview 2019 PRIOR AUTHORIZATION CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview UCare requires your physician to get prior authorization for certain drugs. This means that

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

Biologics for Autoimmune Diseases

Biologics for Autoimmune Diseases Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines

More information

2017 PRIOR AUTHORIZATION CRITERIA

2017 PRIOR AUTHORIZATION CRITERIA 2017 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) UCare requires your physician to get prior authorization for certain

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) CIMZIA (certolizumab pegol) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

More information

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)

More information

Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD

Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):

More information

Otezla. Otezla (apremilast) Description

Otezla. Otezla (apremilast) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

More information

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 9 Last Review Date: June 22, 2018 Afinitor Description Afinitor and

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date: Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber

More information

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical Guidelines Flebogamma IVIG Per Medical Guidelines Gammagard IVIG/SCIG Per Medical Guidelines

More information

2018 Prior Authorization (PA) Criteria

2018 Prior Authorization (PA) Criteria 2018 Prior Authorization (PA) Certain drugs require prior authorization from EmblemHealth Medicare PDP Medicare Plans. This means that your doctor must contact us to get approval before prescribing the

More information

TYSABRI FOR CROHN S DISEASE

TYSABRI FOR CROHN S DISEASE TYSABRI FOR CROHN S DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses Actemra ACTEMRA INTRAVENOUS All medically accepted indications not otherwise excluded plus patients already started on tocilizumab for a covered use. Castleman's disease. Still's disease. Concurrent use

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If

More information

Injectable Drugs Requiring Pre-Service Approval

Injectable Drugs Requiring Pre-Service Approval Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients

More information

2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements

2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements 2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements You may need prior authorization for certain drugs that are on the formulary or drugs that are not on the formulary.

More information

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage Drugs That Require Prior Authorization (PA) Before Being Approved for You will need authorization by BlueCross BlueShield of WNY Retiree Pharmacy PDP (PDP) plan before filling prescriptions for the drugs

More information

FYI ONLY Generic Name. Generics available. zoledronic acid N/A

FYI ONLY Generic Name. Generics available. zoledronic acid N/A Criteria Document: Reference #: PC/A011 Page 1 of 5 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community

More information

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

Approval of a drug under this criteria document does not ensure full coverage of the drug.

Approval of a drug under this criteria document does not ensure full coverage of the drug. Criteria Document: Reference #: PC/A011 Page 1 of 8 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community

More information

COSENTYX (secukinumab)

COSENTYX (secukinumab) COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date: Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date: Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP

More information

2016 Prior Authorization (PA) Criteria

2016 Prior Authorization (PA) Criteria 2016 Prior Authorization (PA) Certain drugs require prior authorization from EmblemHealth Medicare HMO/PPO Medicare Plans. This means that your doctor must contact us to get approval before prescribing

More information

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64 Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra

More information

Infliximab/Infliximab-dyyb DRUG.00002

Infliximab/Infliximab-dyyb DRUG.00002 Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration

More information

MEDICATION(S) ACTEMRA 200 MG/10 ML VIAL, ACTEMRA 400 MG/20 ML VIAL, ACTEMRA 80 MG/4 ML VIAL

MEDICATION(S) ACTEMRA 200 MG/10 ML VIAL, ACTEMRA 400 MG/20 ML VIAL, ACTEMRA 80 MG/4 ML VIAL ACTEMRA ACTEMRA 200 MG/10 ML VIAL, ACTEMRA 400 MG/20 ML VIAL, ACTEMRA 80 MG/4 ML VIAL All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on tocilizumab (IV or

More information

Updated 09/2018. Concurrent Use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or Targeted Synthetic DMARD.

Updated 09/2018. Concurrent Use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or Targeted Synthetic DMARD. Updated 09/2018 ACTEMRA ACTEMRA Covered Uses All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on tocilizumab (IV or SC) for a Covered Use. Concurrent Use with

More information

TYMLOS (abaloparatide)

TYMLOS (abaloparatide) TYMLOS (abaloparatide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Infliximab, Infliximab-dyyb, Infliximab-abda File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab 5/2002 2/2018 2/2019 7/2018 Description of Procedure

More information

Remicade (infliximab) DRUG.00002

Remicade (infliximab) DRUG.00002 Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi

More information

List of Designated High-Cost Drugs

List of Designated High-Cost Drugs List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 11.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab_remicade 5/2002 2/2017 2/2018 2/2017 Description of Procedure or Service Infliximab (REMICADE

More information

STELARA (ustekinumab)

STELARA (ustekinumab) STELARA (ustekinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis

More information

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) ACTEMRA (tocilizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language

More information

Actemra. Actemra (tocilizumab) Description

Actemra. Actemra (tocilizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra

More information

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014 Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT

More information

Clinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63

Clinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Effective Date: 01/18 Last Review Date: Coding Implications Revision Log Description The intent of the criteria is to ensure

More information

Amjevita (adalimumab-atto)

Amjevita (adalimumab-atto) *- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled

More information

NB Drug Plans Formulary Update

NB Drug Plans Formulary Update Bulletin # 967 February 12, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective February 12, 2018. Included in this bulletin: Regular Benefit Additions

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)

More information

2018 PRIOR AUTHORIZATION CRITERIA

2018 PRIOR AUTHORIZATION CRITERIA 2018 PRIOR AUTHORIZATION CRITERIA UCare for Seniors Classic (HMO-POS) UCare for Seniors Value Plus (HMO-POS) UCare for Seniors Essential Rx (HMO-POS) UCare for Seniors Standard (HMO-POS) UCare for Seniors

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

2018 PRIOR AUTHORIZATION CRITERIA

2018 PRIOR AUTHORIZATION CRITERIA 2018 PRIOR AUTHORIZATION CRITERIA UCare for Seniors Classic (HMO-POS) UCare for Seniors Value Plus (HMO-POS) UCare for Seniors Essential Rx (HMO-POS) UCare for Seniors Standard (HMO-POS) UCare for Seniors

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab

More information

BONIVA (ibandronate sodium)

BONIVA (ibandronate sodium) BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

3. Has the patient shown improvement in signs and symptoms of the disease? Y N Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax

More information

2019 PRIOR AUTHORIZATION CRITERIA

2019 PRIOR AUTHORIZATION CRITERIA 2019 PRIOR AUTHORIZATION CRITERIA UCare Medicare Classic (HMO-POS) UCare Total (HMO-POS) UCare Essentials Rx (HMO-POS) UCare Standard (HMO-POS) UCare Prime (HMO POS) Care Core with Fairview & North Memorial

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of

More information

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

Simponi / Simponi ARIA (golimumab)

Simponi / Simponi ARIA (golimumab) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi

More information

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual

More information

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your BlueSaver HMO, Senior Blue HMO or Forever Blue PPO plan before filling prescriptions for

More information

Stelara. Stelara (ustekinumab) Description

Stelara. Stelara (ustekinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)

More information

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N 12/21/2016 Prior Authorization Aetna Better Health of West Virginia Humira (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

Mountain Health Trust/WV Health Bridge

Mountain Health Trust/WV Health Bridge Mountain Health Trust/WV Health Bridge Preferred Drug List (PDL) The West Virginia Preferred Drug List (PDL) is a list of medications recommended to BMS by the West Virginia Medicaid Pharmaceutical and

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: CP.PHAR.63 Effective Date: 06.01.11 Last Review Date: 08.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),

More information